Medication¶
Summary¶
This chapter explains ADHD medication without hype or fear: how stimulants and non-stimulants work, what titration is, what side effects to watch, and how to track whether a medication is actually helping. It treats the decision to medicate as exactly that — a decision, made with a prescriber, revisited over time. After this chapter, readers can have an informed conversation with a clinician and know what questions to ask.
Concepts Covered¶
This chapter covers the following 25 concepts from the learning graph:
| Concept | CIS Score |
|---|---|
| Medication Overview | 62 |
| Stimulant Medications | 10 |
| Methylphenidate | 1 |
| Amphetamine Medications | 1 |
| Non-Stimulant Medications | 4 |
| Atomoxetine | 1 |
| Guanfacine | 1 |
| Off-Label Options | 1 |
| How Stimulants Work | 3 |
| Dopamine Reuptake | 1 |
| Medication Onset And Duration | 1 |
| Immediate Vs Extended Release | 1 |
| Titration | 3 |
| Finding The Right Dose | 2 |
| Side Effects | 5 |
| Appetite And Sleep Effects | 1 |
| Cardiovascular Considerations | 1 |
| Medication Holidays | 1 |
| Stimulant Misconceptions | 1 |
| Controlled Substance Rules | 2 |
| Medication Shortages | 1 |
| Tracking Medication Response | 1 |
| Medication And Comorbidities | 1 |
| Talking To Your Prescriber | 1 |
| Deciding About Medication | 1 |
Prerequisites¶
This chapter builds on concepts from:
No ADHD topic carries more freight than medication. One grandparent is sure it's overprescribed mind control; one influencer is sure it's a miracle everyone's being denied; and somewhere between them a family sits with an actual decision to make. This chapter clears the freight. It explains what the medications are, how they work in the brain you studied in Chapter 2, what the honest costs and limits are, and how to run the decision like the informed participants Chapter 5 trained you to be.
Two boundaries, stated up front because they're load-bearing. This book gives no dosing advice and recommends no specific medication for any specific person — that is the prescriber's job, done with a medical history in hand. And medication is a choice, not a consequence of diagnosis: some people take it and call it life-changing, some try it and stop, some never start, and all three can be reasonable outcomes of a good decision process. What this chapter guarantees is that your version of that process will be informed.
The most loaded topic in the book
One grandparent is certain it's overprescribed mind control; one influencer is certain it's a miracle. This chapter clears the freight so you can make an actual decision — which is what this is, not a consequence of the diagnosis. I'll sit with you.
The Lay of the Land¶
The medication overview in one honest paragraph: ADHD medications are the most-studied psychiatric medications in children and among the best-evidenced treatments in all of psychiatry. They divide into two families — stimulants and non-stimulants. Stimulants are the first-line treatment in most guidelines because their evidence is strongest: across the two stimulant classes, roughly 70-80% of people respond meaningfully. They begin working within an hour of a dose and stop when the dose wears off — which makes them unusually testable: a trial tells you something in weeks, not months. Non-stimulants are the smaller, slower-acting family — genuine alternatives when stimulants don't fit. What medication does, when it works, follows straight from Chapter 2: it raises dopamine and norepinephrine signaling in the prefrontal circuits that do the steering, so regulation improves — attention holds longer, the brake works faster, the noise quiets. What it doesn't do matters just as much, and deserves its own early sentence: pills don't build skills. Medication can make the executive machinery work better for some hours a day; it doesn't install routines, teach planning, repair a relationship, or organize a backpack. The families who report the best outcomes treat medication — when they choose it — as one pillar alongside the skills, systems, and structures of Chapters 8 through 10, not as the whole building.
A worked example of the overview doing its job, before the details: Sana (Chapter 4), newly diagnosed at 24, tells her parents she's considering medication. Her father's instinct is alarm — "you've managed this long without drugs." Her mother's is over-correction — "finally, this will fix everything." The chapter you're reading is the answer to both: to her father, that managing "this long" had costs he read about in the burnout section of Chapter 6, that stimulants are short-acting and testable, and that a trial is not a lifetime sentence; to her mother, that medication may give Sana back some hours of steerable attention, and that what Sana builds in those hours — the systems of Part Three — is where the life change actually lives. The realistic expectation sits between their two fears: a meaningful tool, probably; a cure, no.
The Stimulants¶
Stimulant medications are the family most people mean by "ADHD medication," and the name confuses everyone at the kitchen table, so let's fix that first. They're called stimulants because they increase activity in certain brain systems — and in a brain whose regulation circuits are under-signaling (Chapter 2), stimulating those circuits produces better steering, which often looks from outside like calm. The person isn't sedated; their brake and spotlight finally have adequate signal. That's the whole "paradox" — it was never a paradox, just a misleading category name.
There are exactly two classes, and every brand name you've heard belongs to one of them. Methylphenidate is the first class — the molecule in Ritalin and Concerta, among others. Amphetamine medications are the second — the molecules in Adderall and Vyvanse, among others. The classes are close cousins with slightly different mechanisms (next section) and a practical clinical fact that should lower everyone's stakes: response is individual by class. A person who gets little from one class, or dislikes its side effects, quite often does well on the other — so guidelines treat "try the other class" as a standard early move, and a disappointing first trial means much less than families fear.
How stimulants work is Chapter 2 vocabulary in action. Dopamine reuptake is the recycling step in neural signaling: after a neuron releases dopamine into a synapse, transporter proteins vacuum it back up, ending the signal. Methylphenidate works mainly by blocking that vacuum — dopamine (and norepinephrine) linger longer, so the signal runs stronger. Amphetamines block the vacuum and nudge neurons to release more in the first place. Either way the destination is the same: stronger dopamine and norepinephrine signaling in prefrontal and reward circuits — the exact systems Chapter 2 identified as under-serving regulation. This is also why the drugs are testable so fast: the mechanism is chemical and immediate, not a slow rebuild.
Medication onset and duration is the practical physics every family scheduling a life around doses needs: stimulants start working roughly 30-60 minutes after swallowing, and their effect ends the same day — nothing accumulates, and each day is its own experiment. The choice within that physics is immediate vs extended release: immediate-release (IR) forms last roughly 3-5 hours — precise, flexible, but requiring midday doses and producing more noticeable "cliffs" as they wear off; extended-release (XR) forms package the same molecules in slow-delivery systems lasting roughly 8-14 hours depending on product — one morning dose covering school or work, smoother curves, at more cost and less flexibility. Real-world regimens are often engineered from both (an XR morning plus a small IR "booster" for evening homework or the after-work hours) — engineered being the operative word, by the prescriber, around when this person's day actually demands regulation. Notice what that implies for families: "the medication wore off" is a real, physical event that happens at roughly the same time every day — the 5 pm irritability isn't a character reversion, it's pharmacokinetics, and it's schedulable-around.
The Non-Stimulants¶
Why the name confuses everyone
They're called stimulants because they raise activity in specific brain systems. In a brain whose regulation circuits are under-signalling, that produces better steering — which looks like calm from the outside. It was never a paradox, just a misleading category name.
Non-stimulant medications are the second family: slower-acting, generally more modest in average effect, and genuinely valuable in specific situations — when stimulants cause intolerable side effects, when they underperform in both classes, when co-occurring conditions (anxiety, tics, substance-use history from Chapter 6) tilt the calculus, when the controlled-substance logistics below are unworkable, or when a person simply prefers to start elsewhere. The two named members: Atomoxetine (Strattera) works by blocking norepinephrine reuptake — the same vacuum-blocking logic, different transmitter emphasis — taken daily, building effect over several weeks (patience is part of the prescription), with no controlled-substance status. Guanfacine (and its cousin clonidine) takes a different road entirely: it stimulates certain norepinephrine receptors (alpha-2) that strengthen prefrontal signaling, and in practice it's used especially in children — often alongside a stimulant — with particular value for hyperactivity, impulsivity, emotional reactivity, and sleep-onset trouble. A newer non-stimulant, viloxazine, works along atomoxetine-like lines. Off-label options rounds out the map: prescribers sometimes use medications approved for other conditions — most commonly bupropion (an antidepressant with dopamine-norepinephrine activity), occasionally modafinil or others — when the standard menu hasn't fit; "off-label" means "outside the approved indication," which is legal, common across medicine, and reasonable to ask direct questions about, starting with "what's the evidence for this in ADHD?"
Before the process sections, here's the whole menu organized — every row was explained above:
| Family | Members | How it works | Speed | Notes |
|---|---|---|---|---|
| Stimulant: methylphenidate class | Ritalin, Concerta, others | Blocks dopamine/norepinephrine reuptake | Same day | First-line; controlled substance |
| Stimulant: amphetamine class | Adderall, Vyvanse, others | Blocks reuptake + boosts release | Same day | First-line; controlled substance; try-other-class logic applies |
| Non-stimulant | Atomoxetine (Strattera) | Norepinephrine reuptake blocker | Weeks | Not controlled; steady all-day effect |
| Non-stimulant | Guanfacine, clonidine | Alpha-2 receptor agonist | Weeks | Often adjunct in children; helps reactivity and sleep onset |
| Off-label | Bupropion, others | Varies | Weeks | Outside approved indication; ask about evidence |
Titration: The Tuning Process¶
Titration is the deliberate process of finding the right medication and dose by starting low and adjusting stepwise while measuring response — and understanding it converts the messy first months from "this isn't working" despair into "this is the process working." Finding the right dose is genuinely individual: the effective dose correlates poorly with body size, age, or symptom severity — it's a property of an individual nervous system that can only be found empirically. So the prescriber starts at the low end, holds each step for days-to-weeks, collects structured feedback (the tracking section below), and moves up, down, sideways to a different release form, or across to the other class based on what the data says. The realistic timeline families should carry: several weeks to a few months to reach a settled regimen, sometimes with a class switch in the middle — normal, expected, and worth saying out loud to a discouraged teenager mid-process.
A worked example, one titration compressed: Dev's psychiatrist starts a low-dose morning XR (week 1: "maybe something? hard to say"), steps up (week 3: homework starting before 9 pm, teacher notes improved — and appetite at lunch is gone), holds and moves the dose earlier plus adds breakfast-first instructions (week 5: lunch partially back), steps once more (week 7: irritable and flat — too far, and this is the system working, not failing), steps back down (week 8: settled at the week-5 level). Total: two months, one overshoot, one manageable side effect engineered around. That overshoot deserves its sentence: the "zombie" flatness people fear from stimulants is overwhelmingly a wrong-dose phenomenon, and its appearance in titration is information that moves the dose, not a preview of medicated life.
Side Effects, Honestly¶
Flatness is a dose signal
The "zombie" effect families fear is overwhelmingly a wrong-dose phenomenon. If it shows up during titration, that's the process working — it moves the dose. It is not a preview of medicated life.
Side effects are real, mostly manageable, and mostly front-loaded — worst in the first weeks, often easing as the body adjusts or the regimen gets engineered. The honest list for stimulants: reduced appetite (the most common), delayed sleep onset, headaches and stomachaches early on, small increases in heart rate and blood pressure, irritability or emotional flatness (the dose-signal above), and end-of-dose "rebound" — a short window of amplified symptoms as the medication exits, familiar to every parent who's met the 5 pm cliff. Two clusters get their own attention.
Appetite and sleep effects are the daily-management pair. Appetite suppression tracks the medication's active hours — which yields its own workarounds: real breakfast before the dose kicks in, calorie-dense options at the times hunger returns, dinner after wear-off, and in children, growth tracked at checkups (research shows small average effects on growth trajectory — a monitoring item, not an alarm). Sleep-onset delay compounds Chapter 6's existing ADHD sleep story; the levers are dose timing, release-form choice, and honest reporting — and untangling "medication insomnia" from the pre-existing 1 am body clock is exactly the kind of question prescribers need your data for. Cardiovascular considerations are the reason for the screening questions at the first appointment: personal heart history, fainting, family history of early cardiac events. For healthy people the increases are small and well-tolerated; for specific cardiac histories, the prescriber may involve cardiology first. Take the screening seriously, answer it completely, and then let its results — not internet fear — set your level of concern.
Medication holidays — planned breaks, classically summers or weekends for children — are a legitimate tool with genuine trade-offs: breaks can restore appetite and check whether the medication is still needed at this dose, but they also unmedicate the summer's social learning, the weekend's family life, and (for teens) the Saturday driving that Chapter 4 flagged as a safety topic. Current practice treats holidays as an individual decision with the prescriber, not a default; the question to bring is "what would we be resting, and what would we be giving up?"
The Noise: Misconceptions, Rules, and Shortages¶
Stimulant misconceptions deserve a rapid, referenced teardown, because every family hears all of them. "It will change her personality" — at the right dose, people report being more themselves, with working brakes; flattening is a wrong dose (see titration). "It's basically legal meth" — the molecules are related and the medical formulations, doses, and delivery are engineered exactly opposite to abuse pharmacology; slow delivery to the brain is the safety feature. "It leads to addiction" — Chapter 6's evidence again: treated ADHD shows neutral-to-protective effects on substance risk versus untreated. "It's cheating" — glasses aren't cheating at seeing; Chapter 1's willpower myth in a new costume. "Everyone builds tolerance and needs more forever" — dose adjustments over years happen (bodies grow, lives change); runaway escalation is not the typical course and is exactly what prescriber monitoring exists to catch. "If it works, that proves ADHD" — stimulants sharpen most people's focus somewhat; response is not diagnostic, which is why Chapter 5's evaluation came first.
Controlled substance rules are the logistics tax on stimulant treatment, worth knowing in advance so they're annoying instead of alarming: in the US, stimulants are Schedule II — typically no automatic refills (a new prescription each month), quantity limits, ID checks at pharmacies, state monitoring databases, and rules about early refills and travel. The unfunny irony is that this system demands monthly executive function from the population least equipped for it — so treat refill logistics as a Chapter 9 system from day one: calendar alarms for reorder day, pharmacy apps, and (for the family) an agreed reminder protocol rather than an ad-hoc nag. Medication shortages have been a real recurring feature since 2022, especially for amphetamine-class products: practical moves are refilling on the earliest allowed day, calling pharmacies before transferring prescriptions (stock varies block to block), asking the prescriber about equivalent alternatives when a specific product is dry, and never stretching doses silently — tell the prescriber and re-plan together.
Knowing Whether It's Working¶
Ten minutes a week
Before starting, write down three to five concrete things you'd expect to change — homework started before 8pm, mornings without a fight. Rate them weekly with side-effect notes and times of day. That sheet is what turns anecdotes into dosage decisions.
Tracking medication response is the difference between "I think he seems better?" and an actual titration signal, and it's the family's biggest contribution to the whole process. The method is simple and worth doing formally for the first months: before starting, write down the three-to-five target problems that matter most in this household (homework started before 8 pm; morning routine without a fight; meetings survived without a phone spiral — concrete, observable, yours); rate them for a baseline week; then rate them briefly each week of titration, alongside side-effect notes with times of day. Add collateral (Chapter 5's lesson applies here too — teacher input for children, partner observations for adults, since self-report on one's own attention is exactly what ADHD makes unreliable). Bring the sheet to every appointment. Ten minutes a week converts anecdotes into dosage decisions.
Diagram: Titration Response Tracker¶
Run the Titration Response Tracker fullscreen
Titration Response Tracker
Type: microsim
sim-id: titration-response-tracker
Library: Chart.js
Status: Specified
Learning objective: Apply (L3, Bloom verb: use) structured response-tracking by working through a simulated titration — setting target symptoms, rating weekly data, and reading the resulting curves the way a prescriber would.
Canvas layout: Responsive. Top: a line chart, x-axis = weeks 0-10, y-axis = rating 0-10, plotting 3 target-symptom series plus a side-effect burden series. Bottom: controls and a decision panel.
Visual elements:
- Preloaded scenario: Dev's titration from the chapter (baseline week 0; small change week 1; improvement weeks 3-5 with an appetite dip; overshoot flatness week 7; settle week 8), each dose step marked as a vertical annotation line with the step labeled ("start low XR", "step up", "step up again", "step back")
- Hovering any data point shows the week's diary note ("teacher reports assignments arriving; lunch untouched")
- The learner can toggle each series and drag a "what matters most" weight slider that recomputes a composite response score
Interactive controls:
- "Decision mode": at weeks 3, 5, and 7 the chart pauses and asks the learner what the prescriber should do next (hold / step up / step down / switch class / engineer around side effect), then reveals what was done and why, with explained feedback
- "Blank tracker" mode: learner defines 3 target symptoms in text fields and rates 2 weeks of hypothetical data to practice the setup they'd use at home; a print/copy view formats it as a take-to-appointment sheet
- Reset and scenario-replay buttons
Data visibility requirements:
- Stage 1: Baseline ratings visible before any dose line
- Stage 2: Every dose change annotated at its week with visible before/after slopes
- Stage 3: Decision-mode feedback names the data feature that drives the call (e.g., "flat affect appearing while targets plateau = overshoot")
- Final: Blank-tracker output shows the exact sheet structure the chapter recommends
Instructional rationale: The chapter's claim is that structured tracking converts anecdote into titration signal; letting the learner read curves and make the dose-step calls (with feedback) rehearses that skill directly, and the blank mode transfers it home.
Implementation: Chart.js with annotation plugin behavior implemented in config; responsive; no external data.
Medication and comorbidities is the tracking topic's advanced level, connecting straight back to Chapter 6: co-occurring conditions change both the choice and the reading of results. Anxiety can sharpen slightly on stimulants for some people and improve for others (often, when the anxiety was running on executive chaos); depression severe enough to flatten engagement may need treatment first; tics need monitoring (with Chapter 6's caution about their natural waxing); sleep problems tangle with dose timing; and substance-use history shifts prescribers toward long-acting formulations or non-stimulants with lower diversion potential. None of this is yours to engineer — it's yours to report, completely, so the person engineering it has the full board in view.
Running the Decision¶
Talking to your prescriber works best as a prepared conversation between collaborators, so bring: the target-symptom list and tracking sheet; complete honesty about sleep, substances (including caffeine and cannabis — the prescriber is calibrating chemistry, not conducting a morality audit), and whether doses are actually being taken (missed doses are data, not a confession — and a solvable Chapter 9 problem); every side effect with its time of day; and your questions, of which the all-purpose best is "what would make us adjust, and what are we watching for?" For teens and adult children, one structural note for the family: the prescriber relationship belongs to the patient — a parent's role shifts from running the appointment (age 9) to supplying collateral from the waiting room (age 16) to nothing-unless-invited (age 24), and Chapter 14 has more to say about that curve.
Deciding about medication — the chapter's destination — is a weighing, not a verdict, and here is the honest scale. On one side: the strongest evidence base in the field; fast, testable trials (for stimulants); effects families describe as finally-the-volume-knob-works; and downstream benefits documented in research from academics to driving safety (Chapter 4). On the other: real side effects and their management load; the logistics tax; the unfinished question of what suits this body, answerable only by trying; and legitimate personal values about medication that deserve respect rather than debate tactics. Three framings that reliably help families stuck at this fork. A stimulant trial is reversible — same-day pharmacology means stopping returns you to baseline; the decision is closer to "run an experiment" than "choose a life." The comparison isn't medication versus nothing — it's medication versus the status quo's costs, which Chapter 6's burnout and chronic-stress sections priced honestly. And the decision is renewable: right-for-now gets revisited at every life stage, and both starting and stopping are decisions to make with the prescriber rather than by silent drift. Whatever this family decides, the next chapter exists either way — because pills don't build skills, and skills are where we go now.
For both readers
Before the prescriber appointment, each of you independently writes the three changes you'd most hope to see from treatment. Compare. If the person with ADHD writes "less exhausting to be me" and the family writes "remembers the trash," you've just discovered you're solving different problems — better to find out at the kitchen table than three months into titration.
Check yourself: two weeks into a stimulant trial, a 10-year-old is doing homework without battles — but she's flat at dinner, barely touching food, and up past 11. Her parent concludes 'the medication isn't for her' and wants to stop. What does this chapter say? Click to check.
Every item on that list is a titration signal, not a verdict. Flatness suggests the dose may be too high (the overshoot pattern — moves the dose, doesn't end the trial); appetite suppression is the most common side effect with standard engineering responses (breakfast before dose, dense calories at wear-off, growth monitoring); sleep delay responds to dose timing and release-form changes — and needs untangling from any pre-existing ADHD sleep phase. The homework result shows real target-symptom response, which is exactly what you'd hate to abandon unexamined. The chapter's move: record all of it with times of day, report to the prescriber, and let the process adjust — two weeks into titration is the middle of the experiment, not its conclusion. (And if, after proper adjustment, the trade-offs still aren't worth it — stopping is a legitimate outcome of a good process, made with the prescriber.)
You can hold this conversation now
You know the two families, what titration is, which side effects are engineerable, and how to tell whether it's working. Whatever this family decides, the next chapter matters either way — because pills don't build skills.
What to Carry Out of This Chapter¶
For the reader with ADHD:
- Stimulant trials are fast, testable, and reversible — the decision is an experiment, not an identity. And response to one class says little about the other.
- Track your response formally: target symptoms, weekly ratings, side effects with times. Your data drives your titration.
- Tell the prescriber everything — sleep, caffeine, cannabis, missed doses. Calibration, not confession.
For the reader who loves someone with ADHD:
- The 5 pm irritability is pharmacokinetics, not character. Learn the dose curve and schedule around it.
- Your collateral observations are titration data; your job is honest reporting, not dose opinions — and the prescriber relationship belongs to the patient, especially once the patient is grown.
- Zombie flatness means wrong dose, not "what medication does." Report it; don't quietly conclude.
Medication, at its best, buys hours of workable regulation. Chapter 8 is about everything else that treats ADHD — therapy, coaching, exercise, sleep repair — and Chapters 9-10 spend those bought hours building the systems that pills can't.